Skip to main content
Farmacosmo logo

Farmacosmo — Investor Relations & Filings

Ticker · ZJ1 ISIN · IT0005487670 LEI · 815600ABEDB6F0BDDE28 XMIL Wholesale and retail trade
Open in API
Filings indexed 188 across all filing types
Latest filing 2024-01-31 Share Issue/Capital Cha…
Country IT Italy
Listing XMIL ZJ1

About Farmacosmo

https://www.farmacosmo.com/

Farmacosmo is an e-commerce company that operates an online platform for health, beauty, and personal care products. The company's core business is the online sale of a broad range of items, including parapharmaceuticals, supplements, cosmetics, personal care products, baby supplies, and pet care essentials. Managing its platform in-house, Farmacosmo offers a catalog of over 80,000 products from various brands. The company aims to provide a comprehensive wellness destination by combining the offerings of a pharmacy and a cosmetics retailer, supported by expert advice from professionals.

Recent filings

Filing Released Lang Actions
Farmacosmo Risultati Del Secondo Periodo Di Esercizio Dei Warrant Farmacosmo 2022-2025
Share Issue/Capital Change Classification · 99% confidence The document is a formal communication titled 'FARMACOSMO: RISULTATI DEL SECONDO PERIODO DI ESERCIZIO DEI "WARRANT FARMACOSMO 2022-2025"' (Farmacosmo Results of the Second Exercise Period of the 'Farmacosmo Warrants 2022-2025'). It reports on the outcome of a specific corporate action (warrant exercise period) and mentions the remaining warrants and future periods. This type of announcement, which details the results of a specific financial instrument exercise or capital event, fits best under Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS) if no other category is precise enough. Since it directly concerns the status and results of issued warrants (a capital structure element), CAP is the most appropriate specific code. The document is short and acts as a formal announcement, not a comprehensive report like a 10-K or IR.
2024-01-31 Italian
FARMACOSMO: APPROVATO IL CALENDARIO DEGLI EVENTI SOCIETARI 2024
Report Publication Announcement Classification · 99% confidence The document is a formal communication from Farmacosmo S.p.A. to the market, identified by the header "Informazione Regolamentata" (Regulated Information) and the object: "FARMACOSMO: APPROVATO IL CALENDARIO DEGLI EVENTI SOCIETARI 2024" (FARMACOSMO: APPROVED THE CALENDAR OF CORPORATE EVENTS 2024). This document announces the schedule for future corporate events, including board meetings, earnings releases (Q4 2023 data review, Q1, Q2, Q3 reviews), and the Annual General Meeting for the approval of the 2023 Financial Statements. Since this document is an announcement detailing the schedule of future corporate events, it does not constitute the actual financial report (like 10-K or IR) or the actual earnings release (ER). It is a general corporate update regarding future mandatory disclosures and meetings. Given the options, this type of announcement, which sets the timeline for future financial reporting and shareholder meetings, is best classified as a general Regulatory Filing (RNS) or potentially a Report Publication Announcement (RPA) if it were announcing the publication of a specific report. However, since it is announcing the *calendar* of events, and it is a formal regulatory disclosure (REGEM), RNS serves as the most appropriate general regulatory fallback for scheduled corporate activity announcements that don't fit a more specific category like DIV or DIRS. It is not a proxy statement (PSI) or an AGM material (AGM-R) itself, but a notice about them.
2024-01-29 Italian
Farmacosmo In Corso Secondo Periodo Esercizio Warrant
Capital/Financing Update Classification · 98% confidence The document is a press release (COMUNICATO STAMPA) from Farmacosmo S.p.A. dated January 15, 2024. The subject (Oggetto) is 'Farmacosmo In Corso Secondo Periodo Esercizio Warrant' (Farmacosmo Second Exercise Period for Warrants is underway). The text details the terms, dates (January 15 – January 31, 2024), exercise price (€3.04), and procedures for exercising the 'WARRANT FARMACOSMO 2022-2025'. This announcement concerns a specific corporate action related to capital instruments (warrants) and financing structure, but it is not a formal regulatory filing like a 10-K or a comprehensive quarterly report (IR). It is an announcement regarding a capital/financing event. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not a general regulatory filing (RNS) because it fits the specific CAP category better, and it is not an announcement of a report (RPA) as it is the primary communication of the event itself.
2024-01-15 Italian
Il Consiglio Di Amministrazione Approva La Nomina Per Cooptazione Di Mirko De Falco Quale Nuovo Consigliere
Board/Management Information Classification · 99% confidence The document is a formal announcement ('Informazione Regolamentata') from Farmacosmo S.p.A. dated December 15, 2023. The subject ('Oggetto') explicitly states: 'Nomina Per Cooptazione Di Mirko De Falco Quale Nuovo Consigliere' (Appointment by Co-optation of Mirko De Falco as New Director). The body confirms the Board of Directors approved the appointment of a new non-executive director. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-12-15 Italian
Farmacosmo: Ricavi Di Gruppo Dei Primi Nove Mesi Pari A €52,5 Mln (+14% YoY) Trainati Dal Canale Retail Online (+28% YoY)
Earnings Release Classification · 98% confidence The document is titled 'COMUNICATO STAMPA' (Press Release) and its subject is 'Farmacosmo: Ricavi Di Gruppo Dei Primi Nove Mesi Pari A €52,5 Mln (+14% YoY)'. It explicitly states that the Board of Directors reviewed unaudited management data (revenues and key business KPIs) as of September 30, 2023. This structure—a formal announcement releasing key, unaudited financial highlights for a specific interim period (nine months)—is the definition of an Earnings Release (ER). Although it mentions an attachment ('Vedi allegato'), the core content provided is the summary of the results, making ER the primary classification over RPA, especially given the detailed financial figures presented. 9M 2023
2023-10-26 Italian
Farmacosmo - Internal Dealing
Director's Dealing Classification · 100% confidence The document is an official notification published on Euronext Growth Milan. The key indicator is the 'Oggetto' (Subject): 'Farmacosmo - Internal Dealing'. Furthermore, the template title explicitly states: 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.' This directly corresponds to the definition of Director's Dealing (insider trades by management/directors). Therefore, the filing type is DIRS.
2023-10-11 Italian

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.